Milner founded Abcam in a former Cambridge morgue in 1998 after gaining a doctorate in molecular genetics at Leicester University.
Working as a research fellow at Cambridge University, he identified the market opportunity in supplying high-quality antibodies to support protein interaction studies. Abcam supplies more than 45,000 antibodies that track proteins in the human genome project to 50 laboratories worldwide. It floated on AIM in 2005. Profits rose 58.4% in 2009-10, pushing the shares to record levels. Abcam is worth about £690m and Milner has a £93m stake. Share sales add £12m.
Earnings & Financial Data
|
Date |
Category |
Description |
Amount |
|---|---|---|---|
|
2016 |
Asset |
Series A funding for Healx along with Amadeus Capital Partners (Lead) |
$1,425,000 |
|
2016 |
Asset |
Seed funding for GeneAdviser (Lead) |
$332,500 |
|
2016 |
Asset |
Series B funding for Definigen along wiht 5 investors |
$1,425,000 |
|
2016 |
Asset |
Series A funding for SyndicateRoom along with Unicorn AIM VCT |
$2,945,000 |
|
2015 |
Asset |
Seed funding for Eagle Genomics along with 2 investors |
$295,200,000 |
|
2015 |
Asset |
Series A funding for GeoSpock Ltd. along with 3 investors (Lead) |
$5,400,000 |
|
2015 |
Asset |
Venture funding for Desktop Genetics along with 3 investors |
$1,274,000 |
|
2015 |
Asset |
Seed funding for PhoreMost along with 4 investors |
$3,800,000 |
|
2013 |
Sale of Asset |
Venture funding for Horizon Discovery along with 4 investors |
$9,800,000 |
|
2013 |
Asset |
Series C funding for Horizon Discovery along with 10 investors (Lead) |
$4,968,000 |